Abstract:ABSTRACT Objective To evaluate the impact of the first round of the National Centralized Drug Procurement (NCDP) pilot (referred to as “4+7” policy) on the use of policy-related original and generic drugs. Methods Drug purchase data from the China Drug Supply Information Platform (CDSIP) database were used, involving nine “4+7” pilot cities and 12 non-pilot provinces in China. “4+7” policy-related drugs were included, which consisted of 25 “4+7” List drugs and 97 alternative drugs that have an alternative relationship with “4+7” List drugs in clinical use. “4+7” List drugs were divided into bid-winning and non-winning products according to the bidding results. Purchase volume, purchase expenditures, daily costs were selected as outcome variables, and were measured using Defined Daily Doses (DDDs), Chinese Yuan (CNY), and Defined Daily Drug cost (DDDc), respectively. Difference-in-Difference (DID) method was employed to estimate the net effect of policy impact. Results After policy intervention, the DDDs of original drugs among “4+7” List drugs significantly reduced by 124.59%, while generic drugs increased by 52.12% (all p -values <0.01). 17.08% of the original drugs in DDDs were substituted by generic drugs. Prominent reductions of 121.69% and 80.54% were observed in the expenditure of original and generic drugs, with a total cost-saving of 5036.78 million CNY for “4+7” List drugs. The DDDc of bid-winning original and generic drugs, as well as non-winning original drugs, significantly decreased by 33.20%, 75.74%, and 5.35% (all p -values <0.01), while the DDDc of non-winning generic drugs significantly increased by 73.66% ( p <0.001). The use proportion of bid-winning products and non-winning original drugs raised prominently from 39.66% to 91.93% Conclusions “4+7” policy promoted the substitution use of generic drugs against original drugs, which conducive to drug costs saving. The overall quality level of drug use of public medical institutions significantly increased after “4+7” policy, especially in primary medical institutions. Strengths and limitations of this study ➢ The “4+7” policy is the first policy attempt of volume-based drug procurement work at the national level in China, and is a pioneering work in the reform of Drug Supply and Guarantee System in China. This study aimed to explored the effect of this policy on original and generic drug use in China. ➢ This study used data of national database – China Drug Supply Information Platform (CDSIP). The monthly drug purchase data of nine pilot cities and twelve non-pilot provinces in mainland China were analyzed. ➢ This study used Difference-in-Difference analysis to evaluate the policy effect. ➢ The findings based on drug purchase data rather than drug use data in the present study might limit the interpretation and extrapolation of research results.

Evaluation on the Implementation Effect of Centralized Drug Volume-based Procurement in China —Take a General Public Hospital in Chongqing as an Example

Impact of Volume-Based Drug Procurement Policy on Drug Use Structure of Chinese Public Medical Institutions: A Difference-in-Difference Analysis of Nine Pilot Cities and Twelve Non-pilot Provinces

A systematic review on the impact of the volume-based procurement policy on prices and dosages of drugs

Implementation and Impact of National Centralized Drug Procurement Policy in China: Evidence from the National Drug Procurement Database

Impact of ‘4+7’ volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China

"4+7" City Drug Volume-Based Purchasing and Using Pilot Program in China and Its Impact.

The impact of National Centralized Drug Procurement policy on the use of policy-related original and generic drugs in public medical institutions in China: A difference-in-difference analysis based on national database

Impact of China’s National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: an Interrupted Time Series Analysis in Tianjin

The vacated space of volume/price of the drugs centralized procurement with quantity in secondary and above public hospitals of China

The impact of Chinese volume-based procurement on pharmaceutical market concentration

Analysis and discussion on the pharmaceutical centralized procurement implementation — a case study of a large provincial hospital in China

Effects of Volume-Price Contracts on Pharmaceutical Prices: A Retrospective Comparative Study of Public Hospitals in Hubei of China

The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China

Impact and implications of national centralized drug procurement in China

Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series

Analysis of the Effects of the Volume-Based Procurement Policy on the Use of Antihypertensive Drug in a Public Hospital

Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls

Improving access to medicines and beyond: the national volume-based procurement policy in China

Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis

Effect of centralized volume-based procurement of drugs on business performance of listed pharmaceutical enterprises

The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis